Recent developments in the pharmacological treatment and prevention of corneal graft rejection

Bibliography

• THE COLLABORATIVE CORNEAL TRANSPLANTATION STUDIES RESEARCH GROUP: The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation [see comments]. Arch. Ophthalmol (1992) 110:1392–1403.
   Google Scholar
• •An important multi-centre clinical study from the US on the risk factors in corneal transplantation.
   Google Scholar
• BRADLEY BA, VAIL A, GORE SM et al: Penetrating keratoplasty in the United Kingdom: an interim analysis of the corneal transplant follow-up study. Clin. Transpl. (1993):293–315.
   PubMedGoogle Scholar
• •An important multi-centre clinical study from the UK on the factors involved in corneal transplantation.
   Google Scholar
• KIRKNESS CM, FICKER LA, STEELE AD, RICE NS: The success of penetrating keratoplasty for keratoconus. Eye (1990) 4:673–688.
   PubMed Web of Science ®Google Scholar
• FICKER LA, KIRKNESS CM, RICE NS, STEELE AD: Longterm prognosis for corneal grafting in herpes simplex keratitis. Eye (1988) 2:400–408.
   PubMed Web of Science ®Google Scholar
• MEDAWAR PB: The behaviour and fate of skin autografts and homografts in rabbits. Anat. (1944) 78:176–199.
   PubMedGoogle Scholar
• •A classic article on transplantation immunology.
   Google Scholar
• MEDAWAR PB: Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and the anterior chamber of the eye. Br. J. Exp. Pathol (1948) 29:58–64.
   Google Scholar
• •A classic article on immune privilege of the eye.
   Google Scholar
• SONODA Y, STREILEIN JW: Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation (1992) 54:694–704.
   PubMed Web of Science ®Google Scholar
• •An important article on the role of immune privilege of corneal transplantation in murine models.
   Google Scholar
• GRIFFITH TS, BRUNNER T, FLETCHER SM, GREEN DR, FERGUSON TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 270:1189–1192.
   PubMed Web of Science ®Google Scholar
• •An important article on the mechanism of immune privilege.
   Google Scholar
• GRIFFITH TS, YU X, HERNDON JM, GREEN DR, FERGUSON TA: CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity (1996) 5:7–16.
   PubMed Web of Science ®Google Scholar
• DICK AD, SIEPMANN K, DEES C et al:Fas-Fas figand-mediated apoptosis within aqueous during idiopathic acute anterior uveitis. Invest. Ophthalmol Vis. Sci (1999) 40:2258–2267.
   PubMed Web of Science ®Google Scholar
• STUART PM, GRIFFITH TS, USUI N, PEPOSE J, YU X, FERGUSON TA: CD95 figand (FasL)-induced apoptosis is necessary for corneal allograft survival. Clin. Invest. (1997) 99:396–402.
   Google Scholar
• KANG SM, SCHNEIDER DB, LIN Z et al.: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. (1997) 3:738–743.
   PubMed Web of Science ®Google Scholar
• FERGUSON TA: The molecular basis ofanterior associated immune deviation (ACAID). Ocul. Immunol Intim= (1997) 5:213–215.
   PubMed Web of Science ®Google Scholar
• STREILEIN JW, YAMADA J, DANA MR,KSANDER BR: Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant. Proc. (1999) 31:1472–1475.
   PubMed Web of Science ®Google Scholar
• PLSKOVA J, KUFFOVA L, HOLAN V, FILIPEC M, FORRESTER JV: Evaluation of corneal graft rejection in a mouse model. Br. J. Ophthalmol (2002) 86:108–113.
   PubMed Web of Science ®Google Scholar
• WATSCHINGER B, GALLON L, CARPENTER CB, SAYEGH MH: Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation (1994) 57:572–576.
   Google Scholar
• •A seminal article on indirect presentation of antigens.
   Google Scholar
• BENICHOU G, TAKIZAWA PA, OLSON CA, MCMILLAN M, SERCARZ EE: Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. Exp. Med. (1992) 175:305–308.
   PubMed Web of Science ®Google Scholar
• LECHLER RI, BATCHELOR JR: Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. Exp. Med. (1982) 155:31–41.
   PubMed Web of Science ®Google Scholar
• •An important article on the mechanisms of rejection of renal transplantation.
   Google Scholar
• JAGER MJ: Corneal Langerhans cells and ocular immunology. Reg. Immunol (1992) 4:186–195.
   PubMedGoogle Scholar
• ROSS J, HE YG, PIDHERNEY M, MELLON J, NIEDERKORN JY: The differential effects of donor versus host Langerhans cells in the rejection of MHC-matched corneal allografts. Transplantation (1991) 52:857–861.
   PubMed Web of Science ®Google Scholar
• HE YG, NIEDERKORN JY: Depletion of donor-derived Langerhans cells promotes corneal allograft survival. Cornea (1996) 15:82–89.
   PubMed Web of Science ®Google Scholar
• SANO Y, KSANDER BR, STREILEIN JW: Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens. Invest. Ophthalmol Vis. Sri. (1997) 38:1130-1138. An important article on the role of minor antigens in corneal graft rejection in animal models.
   Google Scholar
• NICHOLLS SM, BRADLEY BB, EASTY DL: Effect of mismatches for major histocompatibility complex and minor antigens on corneal graft rejection. Invest. Ophthalmol. Vis. Sci (1991) 32:2729–2734.
   PubMed Web of Science ®Google Scholar
• •See comments on [22].
   Google Scholar
• NICHOLLS SM, WILLIAMS NA: MHC matching and mechanisms of alloactivation in corneal transplantation. Transplantation (2001) 72:1491–1497.
   PubMed Web of Science ®Google Scholar
• CORLEY RB, KINDRED B: In vivo responses of alloreactive lymphocytes stimulated M vitro. Skin graft rejection mediated by MLR-Primed lymphocytes. Scand. Immunol. (1977) 6:991–996.
   Google Scholar
• HARDING FA, MCARTHUR JG, GROSS JA, RAULET DH, ALLISON JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 356:607–609.
   PubMed Web of Science ®Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T cell costimulation. Ann. Rev Immunol. (1996) 14:233–258.
   PubMed Web of Science ®Google Scholar
• TORRES PF, DE VOS AE VAN DER GAAG R, MARTINS B, KIJLSTRA A: Cytokine mRNA expression during experimental corneal allograft rejection. Exp. Eye Res. (1996) 63:453–461.
   PubMed Web of Science ®Google Scholar
• SANO Y, OSAWA H, SOTOZONO C, KINOSHITA S: Cytokine expression during orthotopic corneal allograft rejection in mice. Invest. Ophthalmol. Vis. Sci (1998) 39:1953–1957.
   PubMed Web of Science ®Google Scholar
• YAMADA J, YOSHIDA M, TAYLOR AW, STREILEIN JW: Mice with Th2-biased immune systems accept orthotopic corneal allografts placed in 'high risk' eyes. Immunol. (1999) 162:5247–5255.
   Web of Science ®Google Scholar
• HE XY, CHEN J, VERMA N, PLAIN K, TRAN G, HALL BM: Treatment with interleukin-4 prolongs allogeneic neonatal heart graft survival by inducing T helper 2 responses. Transplantation (1998) 65:1145–1152.
   PubMed Web of Science ®Google Scholar
• PLEYER U, BERTELMANN E, RIECK E HARTMANN C, VOLK HD, RITTER T: Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Craefes Arch. Clin. Exp. Ophthalmol. (2000) 238:531–536.
   PubMed Web of Science ®Google Scholar
• BERTELMANN E, JAROSZEWSKI J, PLEYER U: Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica (2002) 216:2–12.
   Google Scholar
• VAIL A, GORE SM, BRADLEY BA, EASTY DL, ROGERS CA: Corneal graft survival and visual outcome. A multicenter Study. Corneal Transplant Follow-up Study Collaborators. Ophthalmology (1994) 101:120–127.
   Google Scholar
• •An important multi-centre clinical study from the UK on the risk factors in corneal transplantation.
   Google Scholar
• VAIL A, GORE SM, BRADLEY BA, EASTY DL, ROGERS CA, ARMITATE WJ: Clinical and surgical factors influencing corneal graft survival, visual acuity, and astigmatism. Corneal Transplant Follow-up Study Collaborators. Ophthalmology (1996) 103:41–49.
   Google Scholar
• •See comments on [34].
   Google Scholar
• GORMAN SD, CLARK MR: Humanisation of monoclonal antibodies for therapy. &min. Immunol. (1990) 2:457–466.
   Google Scholar
• SAYEGH MH, KHOURY SJ, HANCOCK WW, WEINER HL, CARPENTER CB: Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc. Nati Acad. Sci. USA (1992) 89:7762–7766.
   PubMed Web of Science ®Google Scholar
• •An article on role of oral tolerance in transplant immunology.
   Google Scholar
• HOLAN V, ZAJICOVA A, KRULOVA M, PLSKOVA J, ERIC J, FILIPEC M: Induction of specific transplantation immunity by oral immunization with allogeneic cells. Immunology (2000) 101:404–411.
   PubMed Web of Science ®Google Scholar
• HE YG, MELLON J, NIEDERKORN JY: The effect of oral immunization on corneal allograft survival. Transplantation (1996) 61:920–926.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, GERY I, WEINER HL et al.: Treatment of uveitis by oral administration of retinal antigens: results of a Phase I/II randomized masked trial. Am.' Ophthalmol. (1997) 123:583–592.
   PubMed Web of Science ®Google Scholar
• VAIL A, GORE SM, BRADLEY BA, EASTY DL, ROGERS CA, ARMITAGE WJ: Conclusions of the corneal transplant follow up study. Collaborating Surgeons [see comments]. Br.j Ophthalmol. (1997) 81:631–636.
   PubMed Web of Science ®Google Scholar
• •See comments on [34].
   Google Scholar
• VOLKER-DIEBEN HJ, CLAAS FH, SCHREUDER GM et al.: Beneficial effect of HLA-DR matching on the survival of corneal allografts. Transplantation (2000) 70:640–648.
   PubMed Web of Science ®Google Scholar
• BOISJOLY HM, ROY R, BERNARD PM, DUBE I, LAUGHREA PA, BAZIN R: Association between corneal allograft reactions and HLA compatibility. Ophthalmology (1990) 97:1689–1698.
   PubMed Web of Science ®Google Scholar
• SUGAR A: Clinical ophthalmology. In: Duane's Ophthalmology W Tasman (Ed.), Lippincott Williams, Philadelphia, PA, USA (1997).
   Google Scholar
• DAVID JR, AL-ASKARI S, LAWRENCE HS: Delayed hypersensitivity M vitro. Immunol. (1964) 93:264.
   Web of Science ®Google Scholar
• JONAS JB, RANK RIVI, BUDDE WM: Immunologic graft reactions after allogenic penetrating keratoplasty. Am. j Ophthalmol. (2002) 133:437–443.
   PubMed Web of Science ®Google Scholar
• WIENER E, MARMARY Y, CURELARU Z; The M vitro effect of hydrocortisone on the uptake and intracellular digestion of particulate matter by macrophages in culture. Lab. Invest. (1972) 26:220–226.
   PubMed Web of Science ®Google Scholar
• MELBY JC: Clinical pharmacology of systemic corticosteroids. Ann. Rev Pharm. Toxicol. (1977) 17:511.
   PubMed Web of Science ®Google Scholar
• LEIBOVITZ HM, KUPFERMANN A: Kinetics of topically administered prednisolone acetate. Arch. Ophthalmol. (1976) 94:1387–1389.
   PubMed Web of Science ®Google Scholar
• BUXTON JN, APISSON JG, HOEFFLE FB: Corticosteroids in 100 keratoplasties. Am.j Ophthalmoi (1969) 67:46–51.
   PubMed Web of Science ®Google Scholar
• HILL JC, IVEY A: Corticostemids in corneal graft rejection: double versus single pulse therapy. Cornea (1994) 13:383–388.
   PubMed Web of Science ®Google Scholar
• HUDDE T, MINASSIAN DC, LARKIN DF: Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br. Ophthalmol. (1999) 83:1348–1352.
   PubMed Web of Science ®Google Scholar
• •A randomised study on different treatment modalities used in corneal transplantation.
   Google Scholar
• INOUE K, AMANO S, KIMURA C et al.: Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn.j Ophthalmol. (2000) 44:302–305.
   PubMed Web of Science ®Google Scholar
• PERRY HD, DONNENFELD ED, ACHEAMPONG A et al.: Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAW. (1998) 24:159–165.
   Google Scholar
• HILL JC: Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (1995) 9:422–428.
   PubMed Web of Science ®Google Scholar
• HILL JC: Systemic cyclosporine in high-risk keratoplasty. Short- versus long- term therapy. Ophthalmology (1994) 101:128–133.
   Google Scholar
• HILL JC: The use of cyclosporine in high- risk keratoplasty. Am. Ophthalmol (1989) 107:506–510.
   PubMed Web of Science ®Google Scholar
• •An early study on the role of cyclosporine in corneal transplantation.
   Google Scholar
• REINHARD T, SUNDMACHER R, GODEHARDT E, HEERING P: [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reactions as the only elevated risk factor]. Ophthalmologe (1997) 94:496–500.
   PubMedGoogle Scholar
• ROBERT PY, DELBOSC B, PREUX PM et al.: [Treatment with cyclosporin A, with low doses, in high-risk penetrating keratoplasties. A bi-centric study of 90 cases]. J. Fr. Ophtalmol (1997) 20:507–514.
   Google Scholar
• MILLER K, HUBER C, NIEDERWIESER D, GOTTINGER W: Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation (1988) 45:651–653.
   PubMed Web of Science ®Google Scholar
• BARKER NH, HENDERSON TR, ROSS CA, COSTER DJ, WILLIAMS KA: Current Australian practice in the prevention and management of corneal allograft rejection. Clin. Experiment. Ophthalmol (2000) 28:357–360.
   PubMed Web of Science ®Google Scholar
• •A report on opinions of clinical ophtharnologists in treatment of corneal transplant rejection.
   Google Scholar
• NISHI M, HERBORT CP, MATSUBARA M et al.: Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest. Ophthalmol Vis. Sci. (1993) 34:2477–2486.
   PubMed Web of Science ®Google Scholar
• MILLS RA, JONES DB, WINKLER CR, WALLACE GVV, WILHELMUS KR: Topical FK-506 prevents experimental corneal allograft rejection. Cornea (1995) 14:157–160.
   PubMed Web of Science ®Google Scholar
• KNOLL GA, BELL RC: Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ(1999) 318:1104–1107.
   PubMed Web of Science ®Google Scholar
• SLOPER CM, POWELL RJ, DUA HS: Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology (2001) 108: 1838-1844.
   Google Scholar
• •A clinical report on the use of tacrolirnus in corneal graft rejection.
   Google Scholar
• POLACK FM: Effect of azathioprine (imuran) on corneal graft reaction. Am. Ophthalmol (1967) 64:233–244.
   PubMed Web of Science ®Google Scholar
• FOSTER CS: Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer. Ophthalmology (1985) 92:1436–1439.
   PubMed Web of Science ®Google Scholar
• WIEZORREK R, BIALASIEWICZ AA, ENGELMANN K, GRASEDYCK K, RICHARD G: [Necrotizing keratitis in chronic polyarthritis. Combined immunosuppressive and surgical therapy]. Ophthalmologe (1998) 95:619–624.
   Google Scholar
• THE TRICONTINENTAL MYCOPHENOLATE MOFETIL RENAL TRANSPLANTATION STUDY GROUP: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation (1997) 63:173–174.
   PubMedGoogle Scholar
• KNECHTLE SJ, WANG J, BURLINGHAM WJ, BEESKAU M, SUBRAMANIAN R, SOLLINGER HW: The influence of RS-61443 on antibody-mediated rejection. Transplantation (1992) 53:699–701.
   PubMed Web of Science ®Google Scholar
• TAYLOR DO, ENSLEY RD, OLSEN SL, DUNN D, RENLUND DG: Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. Heart Lung Transplant. (1994) 13:571–582.
   PubMed Web of Science ®Google Scholar
• NOUSARI HC, SRAGOVICH A, KIMYAI-ASADI A, ORLINSKY D, ANHALT GJ: Mycophenolate mofetil in autoimmune and inflammatory skin disorders. Am. Acad. Dermatol (1999) 40(2, Pt 1):265–268.
   Google Scholar
• KILMARTIN DJ, FORRESTER JV, DICKAD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet (1998) 352:35–36.
   PubMed Web of Science ®Google Scholar
• REIS A, REINHARD T, VOICULESCU Aet al.: Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br: J. Ophthalmol (1999) 83:1268–1271.
   Google Scholar
• •A randomised trial on the use of IVIIVIF in high-risk corneal transplantation.
   Google Scholar
• REIS A, MEGAHED M, REINHARD T et al.: Coadministration of the new macrolide immunosuppressant PAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation (2000) 70:1397–1401.
   PubMed Web of Science ®Google Scholar
• NIEDERKORN JY, LANG LS, ROSS J,MELLON J, ROBERTSON SM: Promotion of corneal allograft survival with leflunomide. Invest. Ophthalmol Vis. Sci. (1994) 35:3783–3785.
   PubMed Web of Science ®Google Scholar
• COBBOLD SP, QIN SX, WALDMANN H: Reprogramming the immune system for tolerance with monoclonal antibodies. &min. Immunol (1990) 2:377–387.
   Google Scholar
• COBBOLD SP, MARTIN G, WALDMANN H: The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies. Eur. I Immunol (1990) 20:2747–2755.
   PubMed Web of Science ®Google Scholar
• QIN S, COBBOLD SP, POPE H et al: 'Infectious' transplantation tolerance. Science (1993) 259:974–977.
   PubMed Web of Science ®Google Scholar
• GRACA L, HONEY K, ADAMS E, COBBOLD SP, WALDMANN H: Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. Immunol (2000) 165:4783–4786.
   Web of Science ®Google Scholar
• COBBOLD SP, ADAMS E, MARSHALL SE, DAVIES JD, WALDMANN H: Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev (1996) 149:5–33.
   PubMed Web of Science ®Google Scholar
• •A review article on the immunology and use of mAbs.
   Google Scholar
• IPPOLITI G, FRONTERRE A: Usefulnessof CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant. Proc (1989) 21:3133–3134.
   PubMed Web of Science ®Google Scholar
• IPPOLITI G, FRONTERRE A: Use of locally injected anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant. Proc. (1987) 19:2579–2580.
   PubMed Web of Science ®Google Scholar
• DICK AD, MEYER p, JAMES T et al: Campath-1H therapy in refractory ocular inflammatory disease. Br. Ophthalmol (2000) 84:107–109.
   PubMed Web of Science ®Google Scholar
• NEWMAN DK, ISAACS JD, WATSON PG, MEYER PA, HALE G, WALDMANN H: Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. Eye (1995) 9:564–569.
   PubMed Web of Science ®Google Scholar
• VINCENTI F, KIRKMAN R, LIGHT S et al.: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl. I Med (1998) 338:1700–1701.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, FORTIN E, SCHIFFMAN R et al.: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a Phase I/II clinical trial. Proc. Natl. Acad. Sci. USA (1999) 96:7462–7466.
   PubMed Web of Science ®Google Scholar
• SKURKOVICH S, KASPAROV A, NARBUT N, SKURKOVICH B: Treatment of corneal transplant rejection in humans with anti-interferon-gamma antibodies. Am. I Ophthalmol. (2002) 133:829–830.
   PubMed Web of Science ®Google Scholar
• •An interesting first report on the clinical use of the antibodies.
   Google Scholar
• GEORGE AJ, ARANCIBIA-CARCAMO CV, AWAD HM et al: Gene delivery to the corneal endothelium. Am. I Respic Crit. Care Med (2000) 162:S194–S200.
   PubMed Web of Science ®Google Scholar
• •A review of gene therapy for corneal transplantation particularly looking at different vectors.
   Google Scholar
• WOOD KJ, PRIOR TG: Gene therapy in transplantation. Can: Opin. MM. The]: (2001) 3:390–398.
   PubMed Web of Science ®Google Scholar
• •A review of gene therapy for transplantation.
   Google Scholar
• ORAL HB, LARKIN DF, FEHERVARI Z et al.: Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Tiler: (1997) 4:639–647.
   Web of Science ®Google Scholar
• HOFFMANN F, ZHANG EP POHL T, KUNZENDORF U, WACHTLIN J, BULFONE-PAUS S: Inhibition of corneal allograft reaction by CTLA4-Ig. Graefes Arch. Clin. Exp. Ophthalmol. (1997) 235:535–540.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AM, LAKEY JR, RYAN EA et al: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl. I Med. (2000) 343:289–290.
   PubMedGoogle Scholar